Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.75 |
| ▸ | PI4KA | P42356 | 4/20 | 0.66 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.66 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.66 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.66 |
| ▸ | AHCY | P23526 | 5/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8815696 | 1.00 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12620928 | 0.89 | ADORA2A (0.77) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29135598 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29496348 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29135599 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1982410 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17162883 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL904363 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5810639 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17162884 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13361 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| US-12215343-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-4314297-A1 | TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE | Specific Biologics Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| CN-117083385-A | Targeting oncogenic mutations with double-cleaving endonucleases | 特定生物制品公司 | 2023-11-17 | — | — | CN | claimed |
| WO-2023201203-A2 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-19 | — | — | WO | claimed |
| EP-4240839-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | Specific Biologics Inc. (CA) | 2023-09-13 | — | — | EP | claimed |
| US-8710023-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | claimed |
| US-20140080894-A1 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION | 2014-03-20 | — | — | US | claimed |
| WO-2012119051-A2 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION (US) | 2012-09-07 | — | — | WO | claimed |
| US-20120077866-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | claimed |
| US-8093224-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-20110117646-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7915231-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090275133-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-20060024727-A1 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |